baber/WOPTO huggingface dataset:
Patent AT-E191343-T1 (AT)
Inventor: BODICK NEIL CLAYTON
IPC: A61K31/435
Filed: 1995-10-30
Granted: 2000-04-15
Abstract: The present invention provides the use of a compound <CHEM>  wherein  X is oxygen or sulphur; R is hydrogen, amino, halogen, -CHO, -NO2, -OR<4>, -SR<4>, -SOR<4>, -SO2R<4>, C3-7-cycloalkyl, C4-8-(cycloalkylalkyl), -Z-C3-7-cycloalkyl, and -Z-C4-8-(cycloalkylalkyl) wherein R<4> is straight or branched C1-15-alkyl, straight or branched C2-15-alkenyl, straight or branched C2-15-alkynyl, each of which is optionally substituted with one or more halogens, -CF3, -CN, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C1-4-alkyl, C1-4-alkoxy, -OCF3, -CONH2 or -CSNH2; or R is -OR<5>Y, -SR<5>Y, -OR<5>ZY, -SR<5>ZY, -O-R<4>-Z-R<5> or -S-R<4>-Z-R<5> wherein Z is oxygen or sulphur, R5 is straight or branched C1-15-alkynyl, and Y is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched C1-6-alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G is selected from one of the following azabicyclic rings <CHEM> wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring; R<1> and R<2> may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C1-5-alkyl, straight or branched C2-5 alkenyl, straight or branched C2-5-alkynyl, straight or branched C1-10-alkoxy, straight or branched C1-5-alkyl substituted with -OH, OR<4>, halogen, -NH2 or carboxy; R<3> is H, straight or branched C1-5-alkyl, straight or branched C2-5-alkenyl or straight or branched C2-5-alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is 0, 1 or 2; q is 1 or 2; and --- is a single or double bond; or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of anxiety.
Patent AT-E157738-T1 (AT)
Inventor: RADTKE JOHANNES
IPC: E21D21/00
Filed: 1994-11-11
Granted: 1997-09-15
Abstract: PCT No. PCT/EP94/03730 Sec. 371 Date May 1, 1996 Sec. 102(e) Date May 1, 1996 PCT Filed Nov. 11, 1994 PCT Pub. No. WO95/13453 PCT Pub. Date May 18, 1995An injection cable bolt for anchoring in a bore hole of a rock structure as a pressure hose forming its core and having openings therealong through which the injection medium can be forced through a sheath formed by at least one braided layer of high strength filaments surrounding the core and forming a cable therewith. The braids of the sheath open directly toward the bore wall.
Patent AT-E288270-T1 (AT)
Inventor: MESENS JEAN LOUIS
IPC: A61K9/50
Filed: 1994-11-11
Granted: 2005-02-15
Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.
Patent AT-E169700-T1 (AT)
Inventor: WURSTER HARTMUT
IPC: D21H19/36
Filed: 1995-01-11
Granted: 1998-08-15
Abstract: The present invention relates to a thin printing paper with a weight per unit area in the range below 49 g/m2 and which contains wood and which is provided with surface pigmentation and which incorporates a mixture of a swellable coating silicate (sodium bentonite) and, for the remainder, conventional coating pigments as the pigment and which, in addition, contains only bonding agent that is a natural organic bonding agent, essentially starch. Even if only lightly calendered, the paper is equally well suited for rotogravure printing and for rotary offset printing. It is preferred that the paper also contain a proportion of processed fibres obtained from old-paper.
Patent AT-E183882-T1 (AT)
Inventor: KUENG RUTH
IPC: A01N43/40
Filed: 1991-10-23
Granted: 1999-09-15
Abstract: Fungicidal compsns. contg. (a) RH-7592 or its acid-addn. salts or metal complexes and (b) fenpropidine or its acid-addn. salts are new. RH-7592 is 4-(4-chlorophenyl)-2-phenyl-2-(1H-1,2,4-traixol-1- ylmethyl)-butyronitrile (I) and is described in EP251775. Fenpropidine is 1-(3-(4-t-butylphenyl)-2-methylpropyl)-piperidine (II) and is described in DE2752135.
Patent AT-E199234-T1 (AT)
Inventor: SCHREINER KARL-HEINZ
IPC: B65D25/06
Filed: 1996-06-10
Granted: 2001-03-15
Abstract: The magazine and transporting device (10) is in the form of a pan and is made of plastics. It has a rectangular bottom having side walls (14,16) projecting up from it. At least two opposite side walls are made with an equidistant lattice (22) on their inner sides (18,20). Between the side walls there is at least one partition element (28) fixed temporarily to form a storage sector. This element has a fitting device (32) to fit in the lattice. This is spaced out sideways from the partition element, and is offset to one side from the central axis through the thickness of the partition element.
Patent AT-E180856-T1 (AT)
Inventor: WIEDEMANN KARL
IPC: E03F7/10
Filed: 1996-09-28
Granted: 1999-06-15
Abstract: The dirt accommodation chamber (12) is formed as a treatment chamber provided with a flotation device which when activated feeds in clean water. The accommodation chamber is separated by an overflow weir (11) from an adjacent feed-back chamber (13), which like the dirt accommodation chamber is connectable to the water discharge unit. An outflow aperture is provided which is permeable to floating material.   The dirt accommodation chamber and the feed-back chamber are arranged in a common vessel (2). The dirt accommodation chamber, at least in the area of its side opposite to the feed-back chamber, is raisable to allow the floating layer to float out.
Patent AT-E262020-T1 (AT)
Inventor: EMMRICH GERD
IPC: B01J23/755
Filed: 1996-12-13
Granted: 2004-04-15
Abstract: Recovery of pure aromatics from reformate gasoline comprises: (a) selectively hydrogenating the reformate gasoline, where the conditions are adjusted so that the non-aromatics, esp. olefins, diolefins and triolefins, are hydrogenated; and (b) removing the selectively hydrogenated and aromatics-containing products by extractive distillation and/or by liquid-liquid extraction to aromatics and non-aromatics. An apparatus for carrying out the process is also claimed.
Patent AT-E334960-T1 (AT)
Inventor: FORAT GERARD
IPC: C07B45/04
Filed: 1996-03-22
Granted: 2006-08-15
Abstract: Reagent useful for the synthesis of oxosulphated and fluorinated organic derivs. by reaction with a sulphur oxide, esp. sulphur dioxide, comprises (a) a fluorocarboxylic acid of formula Ea-CF2-COOH (I) (Ea = electron withdrawing atom or group), in the form of a (partial) salt formed with an organic or mineral cation; and (b) a polar aprotic solvent. The mobile proton content of its components, including impurities, is at most equal to half the concn. of (I). Also claimed is the synthesis of only one fluorinated and oxysulphated organic cpd. comprising (a) reacting the above reagent with a sulphur oxide; and (b) heating the resulting mixt. at 100-200 degrees C. for 0.5-10 hrs..
Patent AT-E251862-T1 (AT)
Inventor: JUTO JAN-ERIK
IPC: A61B1/227
Filed: 1996-05-17
Granted: 2003-11-15
Abstract: In a method for positioning the end (63) of a probe (60) on a target surface inside an open cavity in a test object, preferably on the nasal mucous membrane of a human being, the test object is fixed in a given position, whereupon an optical instrument (1) is so adjusted that the target surface is located essentially on its optical axis (I) and the position of the target surface in the longitudinal direction of the optical axis is defined. Then, the probe is attached on a holder (2), which is so operated that the end of the probe is placed essentially on the optical axis and is moved along this axis to the target-surface position defined with the aid of the optical instrument. A device and a system for implementing this method are also disclosed.
Patent AT-E238038-T1 (AT)
Inventor: LIM HOWARD J
IPC: A61K31/135
Filed: 1996-10-09
Granted: 2003-05-15
Abstract: Compositions and methods which are useful for the treatment of solid tumors in a host and which are also useful for increasing the therapeutic index of mitoxantrone in a host. The pharmaceutical compositions are liposomal formulations of mitoxantrone in which the liposomes comprise a mixture of cholesterol and a diacylphosphatidylcholine, preferably 1,2-sn-dimyristoyl-phosphatidylcholine.
Patent AT-E319656-T1 (AT)
Inventor: FOURCOT FABRICE
IPC: B01D53/81
Filed: 1996-10-31
Granted: 2006-03-15
Abstract: A new composition comprises sodium bicarbonate, sodium carbonate and ammonia in the form of ammonium salts. Also claimed is the process for its preparation and its uses. The composition contains at least 70% (more preferably 80% and especially 80 - 95%) of sodium bicarbonate, less than 30% (more preferably less than 20% and especially 5 - 15%) of sodium carbonate, and less than 1% ammonia, as NH4+, (more preferably 0.2 - 0.7%). The preferred composition also contains less than 0.1% of ammonium carbamate (more preferably 0.01 - 0.06%) and less than 10% water(more preferably 1 - 6%). The product is used in the form of a fine powder.
Patent AT-E183938-T1 (AT)
Inventor: GROSSE-PLANKERMANN ANDREAS
IPC: B01D29/00
Filed: 1997-02-05
Granted: 1999-09-15
Abstract: The re-usable water installation comprises an intermediate treatment vessel (6), supplied with used water through a line (7), which filters the water and passes it from there via a pipe (17) to a storage tank (18). The filtration area is automatically variable to match the flowrate of the water supplied to it.
Patent AT-E250822-T1 (AT)
Inventor: BRUCE DAVID J
IPC: H02M3/00
Filed: 1997-04-24
Granted: 2003-10-15
Abstract: The circuit converts a rectified input voltage (Ue) into an AC output voltage (Ua) for operation of a gas discharge lamp (3), with an inductance (L1) connected in series with a switch (S1) across the circuit inputs (1,2) in parallel with a series circuit containing a capacitor (C1) and a second inductance (L2). The junction between the latter capacitor and inductance is connected to one of the input terminals (2) via a second switch (S2), bridged by a diode (D5), connected in series with a second capacitor (C2), with the lamp in parallel with the second switch.
Patent AT-E241934-T1 (AT)
Inventor: GIA SON M
IPC: A61B17/00
Filed: 1997-09-25
Granted: 2003-06-15
Abstract: A vaso-occlusive coil (10) comprises helical windings (11), the end windings (12,13) having a longer pitch than the central windings (14), and provided with a plug (17) in the free ends (15,16) of the coil (10). The coil (10) may be made of a metal of platinum, gold, rhodium, rhenium, palladium, tungsten or alloys. The plug (17) is made from a thermoplastic biocompatible polymer such as polyester, polyamide, or a polyolefin, having a melt temperature in excess of 125 [deg] C. The plug (17) is heated to mould to the coil windings and form a rounded head to insulate and blunt the coil ends. Alternatively, the coil (10) above has a uniform pitch and a clover leaf secondary shape. Alternatively, the coil (10) above has fibres attached to the coil windings, or a polymer strand extending sinusoidally throughout its length. The ends are fused to the polymer plugs. Alternatively, the coil has a plug at one end and a mechanically detachable joint at the other, is detachable via a connective joint susceptible to electrolysis.
Patent AT-E367597-T1 (AT)
Inventor: MORRIS MICHAEL
IPC: G02C7/02
Filed: 1997-01-10
Granted: 2007-08-15
Abstract: A series of progressive ophthalmatic lens elements, each lens element including a lens surface having an upper viewing zone having a surface power to achieve a refracting power corresponding to distance vision; a lower viewing zone having a greater surface power than the upper viewing zone to achieve a refracting power corresponding to near vision; a corridor of relatively low surface astigmatism connecting the upper and lower zones, said corridor having a surface power varying from that of the upper viewing zone to that of the lower viewing zone; the progressive ophthalmic lens series including a first set of lens elements having a base curve(s) suitable fo ruse in providing a range of distance prescriptions for a first category of patient; and a second set of lens elements having a base curve(s) suitable for use in providing a range of distance prescriptions for a second category of patient; each lens element within a set differing in prescribed addition power and including a progressive design, in at lest one of the upper and lower viewing zones, depending upon the addition power of the lens element; the lens elements in the first set differing substantively in progressive design from the corresponding lens elements in the second set due to the differences in base curve(s).
Patent AT-E247090-T1 (AT)
Inventor: HIDAKA HIROYOSHI
IPC: A61K31/495
Filed: 1997-01-31
Granted: 2003-08-15
Abstract: The invention relates to a compound of the following general formula ÄIÜ or a medicinally acceptable salt thereof, or a solvate thereof, <CHEM> wherein R<1> represents alkyl, alkenyl, alkynyl, alkoxy, hydroxy, cyano, or halogen; R<2> represents hydrogen, hydroxy, or halogen; R<3> represents hydrogen, alkyl, or amidino; Ring A represents a 5 to 11-membered cyclic amino group which may be substituted, which cyclic amino group may be bridged between two carbon atoms in optional positions. The compound of this invention is useful for the prevention or treatment of cerebral tissue impairment due to the vasospasm following cerebral hemorrhage.
Patent AT-E223376-T1 (AT)
Inventor: DUBE DANIEL
IPC: C07D317/72
Filed: 1997-03-25
Granted: 2002-09-15
Abstract: The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).
Patent AT-E257644-T1 (AT)
Inventor: JANSEN JOHANNES PETRUS ANTONIU
IPC: A01H1/06
Filed: 1997-06-04
Granted: 2004-01-15
Abstract: Compositae plants is resistant to aphid Nasonovia ribisnigri due to the presence of an Nr resistance gene in the genome, and the compact growth and rapid ageing (CRA) phenotype is not expressed due to absence or deactivation of relevant genetic information in the genome. Also claimed are: (1) a method for producing above plants by: (a) selecting parent plant heterozygous for Nr resistance; (b) manufacturing segregation population and producing progeny from constituent plants; (c) testing for resistance and CRA phenotype and selecting plants either resistant or having no CRA phenotype; (d) producing seed from these by self-pollination and culturing progeny, and (e) testing lines for resistance and CRA phenotype and selecting lines uniformly resistant and uniformly having no CRA phenotype, and (2) generatively or vegetatively produced progeny and parts/derivatives of plants generated in (1), optionally suitable for consumption. NB. CRA is a compact and rapid ageing undesirable phenotype observed in plants homozygous for Nr gene when Nr was inserted into lettuce (Lactuca sativa L.).
Patent AT-E254321-T1 (AT)
Inventor: RAADSEN FERDINAND JAN ANTON
IPC: G07F1/06
Filed: 1997-08-15
Granted: 2003-11-15
Abstract: A gift token has a card-like handy body member with an appropriate imprint and representing a certain exchange-value which is exchangeable for a chosen good. The body member includes an integrated circuit with an electronically readable and programmable memory, intended for the storage (at least temporarily) of the above-mentioned exchange value, in a way which is compatible with an existing electronic payment system.
Patent AT-E218172-T1 (AT)
Inventor: FERRANTE ANTONIO
IPC: B32B5/02
Filed: 1997-09-04
Granted: 2002-06-15
Abstract: The invention concerns anisotropic continuous glass mats containing at least one layer of continuous glass fibres comprising at least 60 % by weight of fibres arranged according to a preferred direction. The invention also concerns a method for obtaining such mats.
Patent AT-E262801-T1 (AT)
Inventor: WENGER LAVON G
IPC: A23N17/00
Filed: 1997-07-02
Granted: 2004-04-15
Abstract: Improved short length extrusion cooking devices (10) are provided which can achieve product throughput and quality characteristics of conventional long-barrel extruders. The short length extruders (10) of the invention include a relatively short barrel (14) having an inlet (18) and an endmost extrusion die (20). An elongated, helically flighted axially, rotatable screw assembly (22) is positioned within the barrel (14) and is coupled to motive means (39, 39a) for rotation of the assembly (22) at a speed of at least about 500 rpm. The device (10) may include an internal, apertured flow-restricting device (60, 102) which defines a mid-barrel choke point for the material being processed. An alternate extruder (120) is configured without a mid-barrel restriction and is designed to operate at essentially atmospheric internal pressure throughout the majority of the length of barrel (122) with a significant pressure rise in the final head (134) adjacent the extrusion die. Preferably, the barrel (14, 122) has an internal bore of generally frustoconical configuration with an effective length to maximum diameter ratio (L/D) of at least about 6. Novel extrusion processes and products are also provided, using extremely short extrusion barrel retention times to give cooked extrudates having essentially no amino acid or vitamin nutrient losses, and/or dense, highly cooked, low moisture feeds. Twin screw extruders (232, 232a) with and without mid-barrel restriction elements (252-256) can also be provided, and include an internally tapered barrel (237) with correspondingly tapered, flighted, axially rotatable screws (238, 240).          00000
Patent AT-E254922-T1 (AT)
Inventor: ILLES JANOS
IPC: A61K31/738
Filed: 1997-09-11
Granted: 2003-12-15
Abstract: The invention relates to pharmaceutical compositions of antimicrobial effect as well as a process for the preparation thereof. The pharmaceutical compositions of the invention comprise zinc or cobalt hyaluronate associate (complex) as active ingredient in admixture with a carrier and/or other additives commonly used in the pharmaceutical industry.
Patent AT-E366314-T1 (AT)
Inventor: MEULENBERG JOHANNA
IPC: G01N33/569
Filed: 1997-10-29
Granted: 2007-07-15
Abstract: The invention comprises a method for generating an infectious clone based on the genome of a positive strand RNA virus which has a genome of at least about 15 kb. The invention further comprises a method for generating an infectious clone based on the genome of an RNA virus, said method further comprising selecting infectious clones by transfecting a host cell with said recombinant nucleic acid whereby said host cell is in essence not susceptible to infection with said virus. The invention further provides modified RNA viruses and vaccines and diagnostic assays derived thereof.
Patent AT-E221546-T1 (AT)
Inventor: JOZEFOWICZ MARCEL PROF
IPC: A61L27/00
Filed: 1998-02-27
Granted: 2002-08-15
Abstract: Preparing materials (I) with anticoagulant properties comprises radical copolymerisation of (a) hydrophobic monomers and (b) hydrophilic monomers with a biospecific function. Also claimed is continuous or discontinuous moulding of (I), in which the homogenous melt in contact with the mould shows a surface tension of more than 50 mN/m.
Patent AT-E208229-T1 (AT)
Inventor: MELDER JOHANN-PETER DR
IPC: C07C69/675
Filed: 1998-06-05
Granted: 2001-11-15
Abstract: Hydroxypivalic acid-neopentyl glycol ester granules (I) are prepared by bringing a hydroxy pivalic acid-neopentyl glycol ester melt (II) onto a cool surface to solidify it. The melt (II) is brought onto the cool surface as a flat layer and is comminuted to form granules (I). The melt (I) contains less than 3 wt.% hydroxy pivalic acid-neopentyl glycol ester crystals. Preferably the melt (II) contains less than 1 preferably 0 wt.% hydroxypivalic acid-neopentyl glycol ester crystals. The sheet is at least 2 mm, preferably 5-20 mm thick. The melt (II) is pre-cooled before being brought onto a continuous cooling band as a flat sheet that is then crushed to form granules.
Patent AT-E222606-T1 (AT)
Inventor: GORMAN KEVIN MATTHEW
IPC: C12N15/09
Filed: 1998-06-24
Granted: 2002-09-15
Abstract: The present invention relates to nucleic acid primers and probes specific for organisms of the Mycobacterium avium complex (MAC) and to their use in nucleic acid amplification methods for the detection and differentiation of such organisms in biological samples. The invention also relates to diagnostic kits for detecting and differentiating the various organisms comprising the MAC.
Patent AT-E370503-T1 (AT)
Inventor: LUSSEY DAVID
IPC: C08L83/04
Filed: 1998-01-23
Granted: 2007-09-15
Abstract: A polymer composition is elastically deformable from a quiescent state. The composition includes at least one electrically conductive filler dispersed within and encapsulated by a non-conductive elastomer, the nature and concentration of the filler being such that the electrical resistivity of the composition is variable in response to distortion forces down to a value substantially equal to that of the conductor bridges of the filler. The composition further includes a modifier which, on release of the distortion forces, accelerates the elastic return of the composition to its quiescent state.
Patent AT-E219516-T1 (AT)
Inventor: BINGHAM BRENDAN WILLIAM
IPC: C12N15/09
Filed: 1998-04-14
Granted: 2002-07-15
Abstract: A MORT1 gene initially cloned from HeLa cells and identified as a member of the receptor mediated apoptotic pathway, is expressed in the human neuronal cell line, NTERA2. Isolation of the MORT1 from this cell line revealed a transcript isoform that differed from the known MORT1 sequence by a deletion of 21 base pairs (bp 172-192 of the coding sequence). Cloning of MORT1 from adult human brain revealed two isoforms, one similarly deleted for bp 172-192, the other with a basepair substitution, A for G at position 173. Assessment of MORT1 function in a yeast two hybrid system indicates that the deleted and intact forms of MORT1 differ in their capacity to interact with other members of the apoptotic pathway.
Patent AT-E232921-T1 (AT)
Inventor: PAASONEN JAN A
IPC: F16C13/00
Filed: 1998-06-11
Granted: 2003-03-15
Abstract: A covered roll structure employed in the manufacture of a paper machine roll comprises a core roll having a substantially cylindrical outer surface, a sleeve of removable material surrounding the core roll outer surface, a sleeve of compressible material surrounding the sleeve of removable material, and a sleeve of polymeric material surrounding the sleeve of compressible material and the sleeve of removable material.